Product Description
An FGFR1c/betaKlotho receptor agonist, which regulates glycolipid metabolism by binding to betaKlotho protein and specifically activating the FGFR1c/betaKlotho receptor complex, thereby mimicking the action of its natural ligand, FGF21 protein. The Product is potentially useful for the treatment of metabolism-related diseases such as dyslipidemia, non-alcoholic steatohepatitis (NASH), type 2 diabetes, and obesity. (Sourced from: https://doc.irasia.com/listco/hk/cspc/announcement/a240517.pdf)
Mechanisms of Action: FGF23 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Jinmante Biotechnology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|